Killing Cancer Update — Saudi FDA Expands ImmunityBio’s ANKTIVA® Use, So Why Not Faster U.S. Access?

 A therapy spotlighted in NewsNation’s “Killing Cancer” special just got broader regulatory traction in Saudi Arabia—but in the U.S., patients still face a maze of approvals, access limits, and insurance barriers. In Episode 74, Steve Gibson asks the questions the media didn’t: if this is real progress, why isn’t access moving faster here?In Logic Dictate Hot Topics — Episode 74, host Steve Gibson delivers a Killing Cancer update tied to the NewsNation special “Killing Cancer: The Power Within,” which featured Dr. Patrick Soon‑Shiong and his company ImmunityBio. Steve’s earlier takeaway: the TV special was important for raising awareness, but it didn’t push hard enough on the tough questions—viability, evidence, adoption, and access. Now there’s a major development: Saudi Arabia’s regulator (SFDA) has announced approvals involving ImmunityBio’s ANKTIVA® (nogapendekin alfa inbakicept)—including use with BCG for BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS, and a conditional/accelerated approval framework in metastatic non‑small cell lung cancer (NSCLC) in combination with checkpoint inhibitors, according to official and company releases. Steve uses that update to sharpen the debate:Why do different regulators move at different speeds—and with different scopes?Why does U.S. access still feel limited for many patients, even when the FDA has already approved ANKTIVA + BCG for a specific bladder cancer indication (April 22, 2024)? How do insurance rules, costs, incentives, and lobbying pressures shape what patients can actually get—in practice, not theory?This episode is political and policy commentary, not medical advice. Always talk with a qualified clinician about diagnosis and treatment options.Learn more about the philosophy behind Logic Dictate: https://www.logicsdictate.com 📘 Read Logic’s Dictate for only $0.99: https://amzn.to/4oAo6AJ